CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Near-Term Commercialization Opportunities from Innovive’s Oncology Portfolio Complement CytRx Molecular Chaperone Pipeline and Technology Platform
25-Sep-2008 -
CytRx Corporation announced the completion of its acquisition of Innovive Pharmaceuticals, Inc. CytRx purchased Innovive for total consideration of approximately 2.6 million shares of CytRx common stock, approximately $18.3 million of future performance-based milestone earn-outs, and the ...
diabetic foot ulcers
diseases
drug development
+4